BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24965414)

  • 1. Retrospective analysis of a large patient sample to determine p53 and Ki67 expressions in renal cell carcinoma.
    Zheng K; Zhu W; Tan J; Wu W; Yang S; Zhang J
    J BUON; 2014; 19(2):512-6. PubMed ID: 24965414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma.
    Gayed BA; Youssef RF; Bagrodia A; Darwish OM; Kapur P; Sagalowsky A; Lotan Y; Margulis V
    BJU Int; 2014 Apr; 113(4):668-73. PubMed ID: 23937277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
    Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
    J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
    Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
    Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
    Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
    J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
    Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
    Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma.
    Serrano MF; Katz M; Yan Y; Kibel AS; Humphrey PA
    Cancer; 2008 Aug; 113(3):477-83. PubMed ID: 18484589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
    Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
    Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.
    Rioux-Leclercq N; Turlin B; Bansard J; Patard J; Manunta A; Moulinoux JP; Guillé F; Ramée MP; Lobel B
    Urology; 2000 Apr; 55(4):501-5. PubMed ID: 10736491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathological prognostic indicators in renal cell carcinoma].
    Rey Rey J; León Ramírez D; López García S; Fernández Vázquez P; Benavente Delgado J; Ojea Calvo A
    Actas Urol Esp; 2010 Jan; 34(1):71-7. PubMed ID: 20223135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
    Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
    J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients.
    Gudbjartsson T; Hardarson S; Petursdottir V; Thoroddsen A; Magnusson J; Einarsson GV
    Eur Urol; 2005 Oct; 48(4):593-600. PubMed ID: 15964127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
    Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
    Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma.
    Toma MI; Weber T; Meinhardt M; Zastrow S; Grimm MO; Füssel S; Wirth MP; Baretton GB
    Cancer Invest; 2011 Feb; 29(2):123-9. PubMed ID: 21210727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).
    Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Carrasco JC; Requena MJ; Montironi R
    Eur Urol; 2004 May; 45(5):606-12. PubMed ID: 15082203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
    Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ;
    Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.